Scholarlink

<p>Artemis is an endonuclease that cleaves DNA hairpins during V(D)J recombination, a critical step enabling coding-joint formation and essential for lymphocyte development. Artemis-deficient severe combined immunodeficiency (ART-SCID) is a monogenic disorder marked by impaired lymphocyte development and poor responsiveness to allogeneic hematopoietic stem cell transplantation. In this study, we explored the use of base editors to correct mutations in the <i>Artemis</i> gene. Specifically, we firstly documented the pathogenic mutations of <i>Artemis</i> from previous studies and newly identified from ClinVar database. Then, we performed ex vivo assays using cytidine base editors (CBEs) to repair the c.181T &gt; C mutation, and adenosine base editors (ABEs) to target the pathogenic c.49G &gt; A and c.404G &gt; A variants associated with ART-SCID. Targeted deep sequencing revealed that rAPOBEC1-SpRY-HF1-BE4max achieved efficient editing (~ 50%) at the c.181T &gt; C site, while ABE8e reached ~ 35% and ~ 20% editing efficiency at the c.49G &gt; A and c.404G &gt; A sites, respectively. Importantly, base editors restored Artemis endonuclease activity in a 293T<sup><i>Artemis</i>−/−</sup> system, with no detectable off-target effects at the predicted sites as assessed by targeted deep sequencing. These findings provide proof-of-concept that base editing can correct ART-SCID-associated mutations, highlighting its potential for future therapeutic development.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Base editing of Artemis mutations ex vivo sheds light on gene therapy for Artemis-deficient SCID

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月15日

查看全文
  • Ziwen Huang,
  • Zhenxi Cai,
  • Peiyang Yan,
  • Yiheng Hu,
  • Ying Wang,
  • Gaijing Zhou,
  • Lisi Deng,
  • Xinli Wang,
  • Zhen Li,
  • Weiting Chen,
  • Xin Tao,
  • Anlong Xu,
  • Shaochun Yuan

摘要

Artemis is an endonuclease that cleaves DNA hairpins during V(D)J recombination, a critical step enabling coding-joint formation and essential for lymphocyte development. Artemis-deficient severe combined immunodeficiency (ART-SCID) is a monogenic disorder marked by impaired lymphocyte development and poor responsiveness to allogeneic hematopoietic stem cell transplantation. In this study, we explored the use of base editors to correct mutations in the Artemis gene. Specifically, we firstly documented the pathogenic mutations of Artemis from previous studies and newly identified from ClinVar database. Then, we performed ex vivo assays using cytidine base editors (CBEs) to repair the c.181T > C mutation, and adenosine base editors (ABEs) to target the pathogenic c.49G > A and c.404G > A variants associated with ART-SCID. Targeted deep sequencing revealed that rAPOBEC1-SpRY-HF1-BE4max achieved efficient editing (~ 50%) at the c.181T > C site, while ABE8e reached ~ 35% and ~ 20% editing efficiency at the c.49G > A and c.404G > A sites, respectively. Importantly, base editors restored Artemis endonuclease activity in a 293TArtemis−/− system, with no detectable off-target effects at the predicted sites as assessed by targeted deep sequencing. These findings provide proof-of-concept that base editing can correct ART-SCID-associated mutations, highlighting its potential for future therapeutic development.